This BA signalling duality manifests through distinct pathways: (1) Nuclear receptor modulation: Although frequently downregulated in CCA (84), FXR activation by CDCA or synthetic agonists (e.g., GW4064) exerts tumor-suppressive effects (75, 76). Here, NR1H4 is linked to cholangiocarcinoma.